Ocular Therapeutix Missed Consensus Estimates

Ocular Therapeutix (OCUL) reported a loss of $0.37 per share on revenue of $10.70 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.29 per share on revenue of $17.08 million. The company missed consensus estimates by 27.59% while revenue fell 27.59% compared to the same quarter a year ago.

Ocular Therapeutix Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.